Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioArctic AB Class B ( ($SE:BIOA.B) ) has shared an announcement.
BioArctic AB’s partner, Eisai, has launched Leqembi Iqlik, a subcutaneous injection for Alzheimer’s maintenance treatment in the U.S., offering a convenient at-home option for patients with early-stage Alzheimer’s. This development is expected to streamline treatment pathways, reduce healthcare resource demands, and enhance patient convenience, potentially strengthening BioArctic’s market position in Alzheimer’s therapies.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a biotechnology company focused on developing treatments for neurodegenerative diseases, particularly Alzheimer’s disease. Their primary product, Leqembi, is an anti-amyloid treatment developed in collaboration with Eisai, targeting both amyloid plaque and protofibrils in Alzheimer’s patients.
YTD Price Performance: 57.09%
Average Trading Volume: 316,010
Technical Sentiment Signal: Buy
Current Market Cap: SEK27.75B
For an in-depth examination of BIOA.B stock, go to TipRanks’ Overview page.